Dr Hamburg is Obama's FDA Commissioner pick
US President Barack Obama has nominated Margaret Hamburg, the Health Commissioner for New York City, to be the next permanent Food and Drug Administration Commissioner, replacing Frank Torti, who has held the position on an acting basis since the New Year. Dr Hamburg's main areas of expertise are considered to be food safety and bioterrorism and the President's remarks in a radio interview about the appointment indicate that contaminated food scandals are a major element of the new Commissioner's remit.
There were effusive messages of support from the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America (PhRMA), with the latter "applauding" the President on "his expeditious selection," not mentioning that this may have been delayed by the fiasco surrounding the nomination of the Secretary of the Department of Health and Human Services (Marketletters passim). The Generic Pharmaceutical Association, which would seem to have rather more cause to be pleased with the new administration, issued a more measured statement, opening with a quote from its president, Kathleen Jaeger, who said: "GPhA stands ready to work with Dr Margaret Hamburg on the critical issues facing the agency as it carries out its mission to protect the public health."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze